1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. North America Epilepsy Drugs Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. North America Epilepsy Drugs Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. North America Epilepsy Drugs Market Regional Analysis
6.2 North America Epilepsy Drugs Market Revenue 2020-2030 (US$ Million)
6.3 North America Epilepsy Drugs Market Forecast Analysis
7. North America Epilepsy Drugs Market Analysis – by Treatment
7.1 First Generation Anti-Epileptics
- 7.1.1 Overview
- 7.1.2 First Generation Anti-Epileptics: North America Epilepsy Drugs Market – Revenue and Forecast, 2020-2030 (US$ Million)
7.2 Second Generation Anti-Epileptics
- 7.2.1 Overview
- 7.2.2 Second Generation Anti-Epileptics: North America Epilepsy Drugs Market – Revenue and Forecast, 2020-2030 (US$ Million)
7.3 Third Generation Anti-Epileptics
- 7.3.1 Overview
- 7.3.2 Third Generation Anti-Epileptics: North America Epilepsy Drugs Market – Revenue and Forecast, 2020-2030 (US$ Million)
8. North America Epilepsy Drugs Market Analysis – by Distribution Channel
8.1 Hospital Pharmacy
- 8.1.1 Overview
- 8.1.2 Hospital Pharmacy: North America Epilepsy Drugs Market – Revenue and Forecast, 2020-2030 (US$ Million)
8.2 Retail Pharmacy Stores
- 8.2.1 Overview
- 8.2.2 Retail Pharmacy Stores: North America Epilepsy Drugs Market – Revenue and Forecast, 2020-2030 (US$ Million)
9. North America Epilepsy Drugs Market – North America Analysis
9.1 Overview
9.2 North America
- 9.2.1 North America Epilepsy Drugs Market Breakdown, by Key
Country, 2023 and 2030 (%)
- 9.2.1.1 North America Epilepsy Drugs Market – Revenue and
Forecast Analysis – by Country
- 9.2.1.1 US:
North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
- 9.2.1.1.1 US: North America Epilepsy Drugs Market Breakdown, by Treatment
- 9.2.1.1.2 US: North America Epilepsy Drugs Market Breakdown, by Distribution Channel
- 9.2.1.2 Canada:
North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
- 9.2.1.2.1 Canada: North America Epilepsy Drugs Market Breakdown, by Treatment
- 9.2.1.2.2 Canada: North America Epilepsy Drugs Market Breakdown, by Distribution Channel
- 9.2.1.3 Mexico :
North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
- 9.2.1.3.1 Mexico : North America Epilepsy Drugs Market Breakdown, by Treatment
- 9.2.1.3.2 Mexico : North America Epilepsy Drugs Market Breakdown, by Distribution Channel
10. Competitive Landscape
10.1 Heat Map Analysis
10.2 Company Positioning and Concentration
11. Industry Landscape
11.1 Overview
11.2 Market Initiative
11.3 Partnerships and Collaborations
11.4 Other Developments
12. Company Profiles
12.1 Abbott Laboratories
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Alkem Laboratories Ltd
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Catalyst Pharmaceuticals Inc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 GSK Plc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Novartis AG
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Pfizer Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Sanofi SA
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Sumitomo Pharma America Inc.
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Teva Pharmaceutical Industries Ltd
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 UCB SA
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
13. Appendix
13.1 About Business Market Insights
13.2 List of Abbreviations
Get Free Sample For North America Epilepsy Drugs Market
